FIGURE SUMMARY
Title

Advances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation

Authors
Fraint, E., Ulloa, B.A., Feliz Norberto, M., Potts, K.S., Bowman, T.V.
Source
Full text @ Stem Cells Transl. Med.
FIGURE 1

Addressing HSCT limitations. Clinical (established) and preclinical (theoretical) advances are informing treatment options for circumventing current HSCT limitation including, A, post‐transplant infection, B, low HSC donor supply, C, inflammation, and D, graft‐vs‐host disease (GVHD). Check mark indicates an established treatment in humans, while open circles signify ongoing preclinical research. BMSC, bone marrow stromal cell; HLA, human leukocyte antigen; HSC, hematopoietic stem cell; HSCT, hematopoietic stem cell transplantation; MPP, multipotent progenitors; ST‐HSC, short‐term HSC
FIGURE 2

Lessons about HSC biology from transplantation and lineage tracing. Differences in how hematopoiesis is sustained were revealed following transplantation (left) or using lineage tracing methods (right). BMSC, bone marrow stromal cell; GVHD, graft‐vs‐host disease; HSC, hematopoietic stem cell; MPP, multipotent progenitor
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Stem Cells Transl. Med.
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.